Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase

Circulation

Volumn 98, Issue 20, 1998, Pages 2117-2125

  Den Heijer, Peter ^a,q   Vermeer, Frank ^b   Ambrosioni, Ettore ^c   Sadowski, Zygmunt ^d   López Sendón, José L ^e   Von Essen, Rainer ^f   Beaufils, Philippe ^g   Thadani, Udho ^h   Adgey, Jennifer ⁱ   Pierard, Luc ^j   Brinker, Jeffrey ^k   Davies, Richard F ^l   Smalling, Richard W ^m   Wallentin, Lars ⁿ   Caspi, Abraham ^o   Pangerl, Andreas ^p   Trickett, Linda ^p   Hauck, Cynthia ^p   Henry, David ^p   Chew, Paul ^p  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d INSTITUTE OF CARDIOLOGY   (Poland)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f Stiftsklinikum Augustinum   (Germany)

^g HÔPITAL LARIBOISIÈRE   (France)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ ROYAL VICTORIA HOSPITAL   (United Kingdom)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k JOHNS HOPKINS HOSPITAL   (United States)

^l UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^m UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁿ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^o KAPLAN HOSPITAL   (Israel)

^p BRISTOL MYERS SQUIBB   (United States)

^q Ignatius Hospital   (Netherlands)

more..

Author keywords

Myocardial infarction; Plasminogen activators; Reperfusion; Thrombolysis; Trials

Indexed keywords

ALTEPLASE; LANOTEPLASE; PLACEBO; PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 0032542048     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.20.2117     Document Type: Article

References (21)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
3. Global Utilization of Streptokinase, and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
4. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
5. Fibrinolylic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
6. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995;91:2725-2732.
7. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD, the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891-898.
8. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346:329-336.
9. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
10. Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem. 1991;266:8156-8161.
11. Collen D, Stassen J-M, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood. 1988;71:216-219.
12. Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood. 1989;73:1842-1850.
13. Hansen L, Blue Y, Barone K, Collen D, Larsen GR. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. J Biol Chem. 1988;263:15713-15719.
14. Liao W-C, Beierle FA, Stouffer BC, Dockens RA, Abbud ZA, Tay LK, Knaus DM, Raymond RH, Chew PH, Kostis JB. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: pharmacokinetic evaluation from InTIME-I study. Circulation 1997;96(suppl I):I-260-I-261. Abstract.
15. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
16. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923-1928.
17. Califf RM, Topol EJ, Stump D, George BS, Boswick JM, Abbottsmith C, Candela R, Kereiakes D, O'Neill W, Stack RS, and the TAMI Study Group. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med. 1988;85:353-359.
18. Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith EW, Stump DC, Boswick J, O'Neill WW, Stack RS, Califf RM, and the TAMI Study Group. Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. Am J Cardiol. 1988;61:723-728.
19. Muller DW, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med. 1990;113:949-960.
20. Califf RM, Newby LK. How much do we gain by reducing time to reperfusion therapy? Am J Cardiol. 1996;78(suppl 12A):8-15.
21. Aufderheide TP, Kereiakes DJ, Weaver WD, Gibler WB, Simoons ML. Planning, implementation, and process monitoring for prehospital 12-lead ECG diagnostic program. Prehospital Disaster Med. 1996;11: 162-171.